Azitra holds $3.8M cash against $3.0M Q3 loss as ATR-04 advances

Image
Azitra holds $3.8M cash against $3.0M Q3 loss as ATR-04 advances

BRANFORD -- November 12, 2026 -- Azitra (NYSE American: AZTR) ended the quarter on September 30, 2026 with $3.8 million in cash and cash equivalents, about 1.3 times its $3.0 million net loss for the quarter. The company says investors in its March 2026 private placement can put in a further $5.25 million to $10.5 million once it reports first-in-human results for its ATR-COSF cosmetic ingredient, which it expects by year-end 2026.

Azitra's quarterly net loss widens 7% while administrative costs stay flat

Net loss was $3.0 million, up from $2.8 million in the third quarter of 2025, an increase of about 7% by FairsOnline's calculation. Research and development expenses rose to $1.3 million from $1.2 million, about 8%. General and administrative expenses were $1.6 million in both periods. Together, R&D and G&A come to $2.9 million, most of the quarter's loss.

The additional investor capital would be sizeable against the balance sheet. The $5.25 million lower bound equals about 1.4 times the $3.8 million cash position, and the $10.5 million upper bound about 2.8 times. Azitra describes the money as an opportunity for investors, not a commitment: it lists non-exercise of the instruments, in whole or in part, among its risk factors. The company did not disclose how long its current cash will fund operations.

Azitra's ATR-04 trial moves to Cohort 2 with about 24 patients

Azitra completed Cohort 1 of the Phase 1/2 trial of ATR-04, an investigational live biotherapeutic for skin rashes linked to cancer treatment. The safety review committee recommended proceeding to Cohort 2. Cohort 2 is expected to enroll approximately 24 patients on once-daily treatment for 28 days.

The company widened eligibility to patients with rash associated with KRAS and MEK inhibitors, including patients with neurofibromatosis type 1 whose rash is linked to MEK inhibitors. It also modified trial requirements to facilitate recruitment. Azitra warns that the expanded populations may show different safety or efficacy profiles.

Topline data from Cohort 1 are expected in the fourth quarter of 2026. Azitra holds FDA Fast Track designation for cancer treatment-associated rash, a condition the company says affects up to 300,000 people in the U.S.

Azitra's 50% wrinkle reduction for ATR-COSF comes from lab tests on human skin

CEO Francisco Salva said a single application reduced the appearance of fine lines and wrinkles by approximately 50% after 48 hours in laboratory studies. He said an optimized formulation improved skin elasticity across every measure tested in a separate study. Both sets of results are ex vivo, and the company says such results may not predict outcomes in humans.

A first-in-human cosmetic study is planned, with initial results expected by year-end 2026. Azitra cautions that the study may be delayed or may not produce favorable results.

Published by:
fairsonline_team
Company
Products